Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT01158352
First received: June 27, 2010
Last updated: September 12, 2013
Last verified: September 2013
  Purpose

Study design:

Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:

  1. Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
  2. Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight

Segment 1

Population:

200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.

Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.

Methods:

Randomization & Blinding:

Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.

Treatment:

Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.

Treatment duration:

The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.

Study Schedule:

Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:

  1. Demographic data, medical history and growth data (month 0):

    Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.

  2. Nutritional assessment
  3. Anthropometric assessment (months 0, 3, 6, 9 12):

    1. Height without shoes
    2. Length
    3. Weight with light cloths and without shoes
    4. MAC
    5. Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
    6. Body composition assessment using the method of bioelectrical impedance
  4. Laboratory parameters (months 0, 6 and 12):
  5. Sleeping Questionaire

Segment 2:

86 subjects and controls will be recruited to segment 2 of the proposed study

Population:

Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study

Control group 1:

Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.

Control group 2:

Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile

Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.


Condition Intervention
Growth
Low Weight
Low Height
Dietary Supplement: Nutritional supplementation formula
Dietary Supplement: Placebo Comparator

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • Height SDS (standard deviation score) [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
    standard deviation score of patient's height at 12 months


Secondary Outcome Measures:
  • Weight SDS (standard deviation score) [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
    Standard deviation score of patient's weight at 12 months

  • Weight/Height SDS (standard deviation score) [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
    Standard deviation score of patient's Weight / Height ratio at 12 months

  • BMI SDS (standard deviation score) [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
    standard deviation score of patient's BMI at 12 months

  • Growth Velocity [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
  • 5.Sleeping Questionaire [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
  • Child Eating Behaviour Questionaire (CEBQ) [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
  • 3-day food diary [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
  • Physical activity questionnaire [ Time Frame: At study entry ] [ Designated as safety issue: No ]

Estimated Enrollment: 286
Study Start Date: November 2010
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nutritional supplemntation formula
Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
Dietary Supplement: Nutritional supplementation formula
Nutritional supplementation formula
Placebo Comparator: Placebo Comparator
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
Dietary Supplement: Placebo Comparator
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals

  Eligibility

Ages Eligible for Study:   3 Years to 8 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for participants at the intervention group (segments 1&2):

  1. Girls aged 3-7 years old and boys aged 3-8 years old
  2. Prepubertal - tanner stage 1
  3. Height, weight and BMI < 10th percentile for age and gender
  4. Availability of growth velocity data for at least 4 months prior to study entry.
  5. Signing inform consent forms

Exclusion Criteria for participants at the intervention group (segments 1):

  1. Diagnosis of GH Deficiency or treatment with GH
  2. Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
  3. Any known gastrointestinal problem including absorption problems
  4. Any known organic reason for slow growth
  5. Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth.

Inclusion Criteria for participants at the control group (segments 2):

  1. Girls aged 3-8 years old and boys aged 3-9 years old
  2. Prepubertal - tanner stage 1
  3. Height ≥ 25th percentile for age and gender
  4. Proper proportion between weight and height- 5th ≤ BMI ≤ 85th
  5. Signing inform consent forms

Exclusion Criteria for participants at the control group (segments 2):

  1. Diagnosis of GH Deficiency or treatment with GH
  2. Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
  3. Any known gastrointestinal problem including absorption problems
  4. Any known organic reason for slow growth
  5. Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth
  6. Children with growth faltering during the previous year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01158352

Locations
Israel
Schneider Children's Medical center
Petaach-Tikva, Israel, 49202
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Moshe Phillip, Prof Schenider Children's Medical
  More Information

No publications provided

Responsible Party: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01158352     History of Changes
Other Study ID Numbers: rmc005547ctil
Study First Received: June 27, 2010
Last Updated: September 12, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Rabin Medical Center:
Growth
Low weight
Low height
Nutritional Formula

Additional relevant MeSH terms:
Weight Gain
Body Weight Changes
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on August 19, 2014